Moerae Matrix, Inc.
Records under this name other than patents Moerae Matrix, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Moerae Matrix, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,562,947 | Compositions and Methods for Preventing or Treating Diseases, Conditions or Processes Characterized by Aberrant Fibroblast Proliferation and Extracellular Matrix Deposition Lapsed on the fee record Ended Feb 18, 2024 · Medium confidence | Lapsed on the fee record | Ended Feb 18, 2024 | Medium confidence |
| US 10,500,249 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition Lapsed on the fee record Ended Dec 10, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 10, 2023 | From the USPTO record |
| US 10,336,788 | Inhibition of cardiac fibrosis in myocardial infarction Lapsed on the fee record Ended Jul 2, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jul 2, 2023 | From the USPTO record |
| US 9,034,815 | Polypeptide for treating or preventing adhesions Lapsed on the fee record Ended May 19, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 19, 2023 | From the USPTO record |
| US 10,087,225 | Formulation of MK2 inhibitor peptides Lapsed on the fee record Ended Oct 2, 2022 · From the USPTO record | Lapsed on the fee record | Ended Oct 2, 2022 | From the USPTO record |
| US 9,999,655 | Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same Lapsed on the fee record Ended Jun 19, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jun 19, 2022 | From the USPTO record |
| US 9,890,200 | Compositions and Methods for Preventing or Treating Diseases, Conditions, or Processes Characterized by Aberrant Fibroblast Proliferation and Extracellular Matrix Deposition Lapsed on the fee record Ended Feb 13, 2022 · Medium confidence | Lapsed on the fee record | Ended Feb 13, 2022 | Medium confidence |
| US 9,642,888 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition Lapsed on the fee record Ended May 9, 2021 · From the USPTO record | Lapsed on the fee record | Ended May 9, 2021 | From the USPTO record |